Literature DB >> 12419829

Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.

Yi-Qing Chen1, Yong-Qing Zhou, Lu-Hong Fu, Dong Wang, Ming-Hai Wang.   

Abstract

The receptor tyrosine kinase RON (recepteur d'origine nantais), a member of the MET proto-oncogene family, has been implicated in the pathogenesis of certain epithelial cancers including lung adenocarcinomas. To determine the oncogenic potential of RON, transgenic mice were generated using the surfactant protein C promoter to express human wild-type RON in the distal lung epithelial cells. The mice were born normal without morphological defects in the lung, however, multiple lung adenomas with distinct morphology and growth pattern were observed. Tumors appeared as a single mass in the lung around 2 months of age and gradually developed into multiple nodules throughout the lung. Most of the tumors were characterized as cuboidal epithelial cells with type II cell phenotypes. They grew along the alveolar walls and projected into the alveolar septa. A transition from pre-malignant adenomas to adenocarcinomas was observed. The RON transgene is highly expressed and constitutively activated in the tumors as evident by immunohistochemical staining and western blot analyses. Moreover, we found that Ras expression was dramatically increased in the majority of tumors. However, no mutation in the 'hot spots' of the K-Ras or p53 gene was observed, although limited genomic instability occurs in individual tumors. Taken together, this is a mouse lung tumor model with unique biological characteristics. The model may provide an opportunity to study the role of RON in lung tumors and to elucidate the mechanisms underlying this distinct lung tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419829     DOI: 10.1093/carcin/23.11.1811

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  14 in total

1.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence.

Authors:  Marceline Côté; A Dusty Miller; Shan-Lu Liu
Journal:  Biochem Biophys Res Commun       Date:  2007-06-18       Impact factor: 3.575

Review 3.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

4.  Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.

Authors:  Ami S Bhatt; Alana Welm; Christopher J Farady; Maximiliano Vásquez; Keith Wilson; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

5.  Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

Authors:  Patricia M LoRusso; Mrinal Gounder; Shadia I Jalal; Valérie André; Siva Rama Prasad Kambhampati; Nick Loizos; Jennifer Hall; Timothy R Holzer; Aejaz Nasir; Jan Cosaert; John Kauh; E Gabriela Chiorean
Journal:  Invest New Drugs       Date:  2017-02-04       Impact factor: 3.850

6.  Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.

Authors:  Tasneem Motiwala; Kalpana Ghoshal; Anindita Das; Sarmila Majumder; Dieter Weichenhan; Yue-Zhong Wu; Kristen Holman; S Jill James; Samson T Jacob; Christoph Plass
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

Review 7.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 8.  Ron-receptor tyrosine kinase in tumorigenesis and metastasis.

Authors:  Mike A Leonis; Megan N Thobe; Susan E Waltz
Journal:  Future Oncol       Date:  2007-08       Impact factor: 3.404

9.  Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer.

Authors:  Nicholas E Brown; Camille Sullivan; Susan E Waltz
Journal:  EMS Cancer Sci J       Date:  2018-07-30

10.  Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.

Authors:  Aaron M Marshall; Rebecca J McClaine; Devikala Gurusamy; Jerilyn K Gray; Kara E Lewnard; Sohaib A Khan; Susan E Waltz
Journal:  Mol Cancer       Date:  2012-01-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.